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ABSTRACT
Mebendazole is a benzimidazole derivative with broad spectrum anthelminthic activity and
excellent tolerability. Orally it is rapidly absorbed and metabolized to sulfoxide and sulfone,
which may be responsible for its anthelminthic action. This research aimed to formulate
mebendazole nanoparticle chewable tablet to increase its dissolution velocity and impact
saturation solubility.
Mebendazole nanoparticle chewable tablets (300 mg) were prepared by direct
compression. The tablets prepared by this method were evaluated by different parameters such
as average weight, hardness, friability, disintegration, drug content and in vitro dissolution etc.
All the parameters were found within the specifications.
The study on the dissolution profile revealed that F1 had better dissolution rate while
compared to F2, F3 and mebendazole microparticle, respectively. Assay values were within the
limits of 90% to 110%.
Keywords: Mebendazole, Nanoparticle, Direct compression, Chewable tablets.
________________________________________________________________________________________________________________
ABSTRAK
Mebendazol merupakan turunan benzimidazol karbamat, sebagai antelmintik berspektrum
luas. Efektif untuk pengobatan penyakit hydatid dan cysticercosis.Absorbsi peroral sangat cepat
dan dimetabolisme menjadi sulfoksid dan sulfon. Penelitian ini bertujuan untuk mendapatkan
tablet kunyah mebendazol nanopartikel untuk meningkatkan kecepatan disolusi dan
kelarutannya.
Tablet mebendazol nanopartikel dosis 300 mg dibuat dengan kempa langsung. Evaluasi
tablet meliputi bobot tablet, kekerasan, kerapuhan, waktu hancur, kandungan obat dan uji
disolusi in vitro.
Semua tablet baik F1 , F2 dan F3 memenuhi persyaratan. Uji disolusi in vitro F1 lebih baik
dibandingkan dengan F2, F3 dan tablet mebendazol mikropartikel. Kandungan obat berada pada
batas yang dipersyaratkan yaitu 90-110 %.
Kata kunci : Mebendazol, Nanopartikel, Kempa langsung, Tablet kunyah
________________________________________________________________________________________________________________
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INTRODUCTION
Human helminthic infestations are
common and have significant worldwide
health implications. They can be
responsible for delayed child growth
and development, probably via a
mechanism of iron-deficient anaemia.
The preferred treatment is anthelmintic
therapy such as pyrantel, albendazole
or mebendazole, all of which are
efficacious and cost effective. Some
encapsulated helminthic infestations
may however require surgical
intervention followed by chemotherapy.
Mebendazole (methyl-5-benzoyl
benzimidazole-2-carbamate), a broad-
spectrum anthelmintic drug of the
benzimidazole class, effective against a
number of nematodal and cestodal
species (Liebenberg et al., 1998), is
recommended for the treatment of non-
surgical cases and as a supplementary
treatment prior to and post-surgery. The
World Health Organization (WHO) has
identified mebendazole as an essential
drug, based upon its clinical efficacy
and low cost. However, it has been
observed that in vivo results are far
from being as effective as those
demonstrated in vitro due to its low
absorption at the gastrointestinal level
Mebendazole (MBZ), IUPAC name
(5-benzoyl-1Hbenzimidazole- 2-yl)-
carbamic acid methyl ester
(C16H13N3O3, MW: 295.293 g/mol,
chemical structure shown in Fig. 1).
Mebendazole is practically insoluble in
water and only 5–10% of the ingested
drug is absorbed from the human
gastrointestinal tract. Drug absorption is
increased when taken with food,
particularly fatty food (Himmelreich et
al., 1977., Ferreira et al., 2010).
An approach that is commonly
used to increase dissolution velocity
and impact saturation solubility of
sparingly soluble compounds such as
mebendaole is to formulate it as
nanometer-sized particles, particles
usually less than 1 μm in diameter.
For example, when the particle size
of the drug is reduced from 8 μm to 200
nm, there is 40-fold increase in the
surface area to volume ratio. This
increase in surface area can provide
substantial increase in the dissolution
rate if the formulation disperses into
discrete particles (Liversidge & Cundy,
1995).
Administration of drugs through
oral route is the most common and the
easiest way to administer a drug.
Figure 1. Chemical structure of mebendazole
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Hence it was decided to formulate
mebendazole chewable tablet to
improve the compliance in children.
Chewable tablets are the tablets which
are required to be broken and chewed
in between the teeth before ingestion.
These tablets are given to the children
who have difficulty in swallowing and to
the adults who dislike swallowing
(Herbert et al, 1989). The advantages
of chewable tablets include palatability,
stability, precise dosing, portability and
ease of delivery. The available literature
suggests that chewable tablets
provides a safe, well-tolerated
alternative to traditional pediatric drug
formulations and offer significant
advantages in children with two years
of age and above (Durga et al, 2010).
In the present paper mebendazole
chewable tablets were prepared by
direct compression methods and all the
three formulas were evaluated. The
main objective of the present study was
to formula and evaluate mebendazole
chewable tablet by direct compression
and to evaluate these using different
parameters.
MATERIALS AND METHODS
Materials
Pure drug sample of mebendazole
was purcased from Indo Farma Ltd. All
other ingredients viz. Lactose
monohydrate, Mannitol, Aerosil,
Magnesium stearate, Aspartame etc
used were of pharmaceutical grade.
Method
Direct Compression
All the ingredients were separately
weighed and sifted using mesh no. 40.
Mebendazole, Mannitol (pearlitol200),
Lactose monohydrate was passed
through mesh no 30. Aspartame,
Yellow color and lemon flavor were
passed through 100 mesh and required
quantities were blended for ten minutes
in poly bag. Finally the above blend
was lubricated with Magnesium
stearate and Aerosil for two minutes.
The powder blend was evaluated for
the flow properties and was found to be
good. The evaluated blend was
compressed into tablets of 1000 mg
weight each. A minimum of fifty tablets
were prepared for each formulas. The
manufacturing formulas for the tablets
used in the above were given in table I.
Evaluation of Tablets
General appearance
The general appearance of tablets,
its visual identity and overall elegance
is essential for consumer acceptance.
The control of general appearance
involves measurement of attributes
such as a tablet’s size, shape, color,
presence or absence of odour, taste,
surface textures, physical flaws and
consistency. Hence the tablets were
checked for the presence of cracks,
depressions, pinholes, uniformity of
color, and the polish of the tablet
(Lachman et al, 1991).
Dimensions
The shape and dimensions of
compressed tablets were determined
by the type of tooling during the
compression process. At a constant
compressive load, tablet thickness
varies with changes in die fill, particle
size distribution and packing of the
powder mix being compressed and with
tablet weight. While with a constant die
fill, thickness varies with variation in
compressive load.
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Table 1: Manufacturing formulas for   preparation of Tablet
No Ingredients F1 (mg) F2 (mg) F3 (mg)
1. Mebendazole 300 300 300
2. Mannitol 300 300 300
3. Lactose monohydrate 368,50 363,50 358,50
4. Aerosil 10 10 10
5. Aspartame 10 10 10
6. Magnesium stearate 5 10 15
7. Yellow colorant 5 5 5
8. Lemon flavour 1,5 1,5 1,5
Total weight (mg) 1000 1000 1000
Tablet thickness is consistent from
batch to batch or within a batch only if
the tablet granulation or powder blends
is adequately consistent in particle size
and particle size distribution, Consistent
length of punch tooling, Tablet press
and good working conditions Thickness
and diameter of the tablets were
measured using digital vernier caliper.
The values of thickness were used to
adjust the initial stages of compression.
Tablet thickness should be controlled
within a ±5% variation of a standard
value. Also the thickness must be
controlled to facilitate packaging
(Lachman et al, 1991).
Hardness
The hardness test is performed to
provide a measure of tablet strength.
Tablets should be hard enough to
withstand packaging and shipping but
not so hard as to create undue difficulty
upon chewing. Tablet hardness is
determined using equipment from
various suppliers that measure the
force needed to break up the tablets.
The Pfizer tester is commonly used.
This tester operates on the same
mechanism principle as a pair of pliers.
As the plier’s handles are squeezed,
the tablet is compressed between a
holding anvil and a piston connected to
a direct force reading gauge. The dial
indicator remains at the reading where
the tablet breaks and is returned to zero
by depressing a reset button (Lachman
et al, 1991).
Friability test
Friability is the loss of weight of
tablet in the container or package, due
to removal of fine particles from the
surface. This parameter was conducted
to ensure the ability of tablets to
withstand the shocks during
processing, handling, transportation,
and shipment. Permitted friability limit is
1.0%. Roche friabilator was used to
measure the friability of the tablets. Ten
tablets were weighed collectively and
placed in the chamber of the friabilator.
In the friabilator the tablets were
exposed to rolling, resulting free fall of
tablets (6 inches) within the chamber of
the friabilator. It was rotated at a rate of
25 rpm. After 100 rotations (4 min.) the
tablets were taken out from the
friabilator and intact tablets were again
weighed collectively (Nandgude et al,
2007., Subhramanyam et al, 2006).
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Disintegration
This test initially may not appear
appropriate for chewable tablets as
these tablets are to be chewed before
being swallowed. However, patients,
especially pediatric and geriatric, have
been known to swallow these chewable
dosage forms. This test would thus
indicate the ability of tablet to
disintegrate and still provide the benefit
of the drug if it is accidentally
swallowed. Tablets should preferably
pass the USP disintegration test for
uncoated tablets.
Weight Uniformity test
Twenty tablets were weighed
individually and all together. Average
weight was calculated from the total
weight of all tablets. The individual
weights were compared with the
average weight. The percentage
difference in the weight variation should
be within the permissible limits. The
percent deviation was calculated using
the following formula (Nandgude et al,
2007., Subhramanyam et al, 2006).
Percentage deviation = [(Individual
weight-Average weight) /Average
weight]×100
In vitro dissolution test
Dissolution measurements were
carried out in a USP dissolution test
apparatus. The dissolution profiles of
mebendazole from chewable tablets
were studied in 0.1 N HCl (pH 1.2). The
chewable tablets containing 300 mg of
mebendazole were placed in a rotating
basket (50 rpm) filled with 900 ml of the
dissolution medium, thermo stated at
37 ± 0.5 OC. At scheduled time intervals
(2 hour), the samples (5 ml) were
withdrawn and replaced immediately
with fresh dissolution medium. The
samples were assayed
spectrophotometrically at 254 nm for
the dissolved drug, where samples
were automatically filtered before
measuring the absorbance against 0.1
N HCl as blank. The amount of
mebendazole released was calculated
from the standard graph (Khokra et al,
2012).
Drug content
Five tablets were powdered and
the blended equivalent to 300 mg of
mebendazole was weighed and
dissolved in suitable quantity of water.
The solution was filtered, suitably
diluted and drug content was analysed
spectrophotometrically at 254 nm. Each
sample was analyzed in triplicate
(Khokra et al, 2012).
RESULTS AND DISCUSSION
All the prepared formulas of tablets
were within the range. Using Monsanto
hardness tester, the strength of the
tablets was tested. All the tablets
showed good hardness. Batch F2 had
minimum hardness (15,99 ± 0,1747)
while F1 and F3 had maximum hardness
16,56 ± 0,2307 and 16,05 ± 0,0723,
respectively. The friability was carried
out for all the formulas of tablets. The
friability was less than 0.2% for all the
blends and was satisfactory. Assay
value of all prepared formulas of
mebendazole tablets were within the
range of 90% to 110% of stated amount
of mebendazole. From the data
obtained it was found that 98,46% of
drug was released for F1 at 120 min
while other tablets F2 and F3 had shown
86,50% and 88,28 % drug release at
120 min respectively. The variation in
F1 MBZ microparticle
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the dissolution rate of mebendazole
tablets was in the following order F1
more superior to F2 and F3.
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Figure 2. Comparison of dissolution profiles of  tablet F1 ( ) and tablet
mebendazole microparticle (     ).
Table 2: Comparative evaluation of tablets
Parameters Tablets code
F1 F2 F3
Weight of tablet  (mg) 996,73 ± 3,0 995,82 ± 2,5 995,91 ± 2,0
Hardness   (kg/cm2) 16,56 ± 0,230 15,99 ± 0,174 16,05 ± 0,07
Friability test  (%) 0,03 ± 0,0058 0,05 ± 0,0116 0,06 ± 0,005
Disintegration time (min) 5 4 3,5
Dissolution  (%) 98,46 86,50 88,28
Drug content (mg) 297 291 285
Assay (%) 99 97 95
The dissolution profile of tablets F1
has shown had better results compared
to the tablets as well as marketed
product mebendazole microparticle as
showed in fig 2.
CONCLUSION
All the tablets showed satisfactory
results with respect to hardness,
friability, assay and in vitro dissolution
studies. Tablets F1 more superior than
F2 and F3. Tablet prepared by direct
compression F1 had the better
dissolution rate when compared F2, F3
and  marketed product mebendazole
microparticle, respectively.
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